Clinical Trials Logo

Clinical Trial Summary

Primary objective

To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men


Clinical Trial Description

Secondary objectives

- To evaluate the tolerability of V503 in 16- to 26-year-old men.

- To summarise humoral immune responses, including anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 GMTs and seroconversion rates at 4 weeks post-dose 3, in 16- to 26-year-old men who received V503 or GARDASIL ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02114385
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date March 24, 2014
Completion date April 22, 2015

See also
  Status Clinical Trial Phase
Completed NCT03584308 - Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal Phase 2
Completed NCT04459221 - Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students Phase 4
Completed NCT05078554 - HPV and Male Homosexuality in General Practice?
Not yet recruiting NCT06416150 - Reducing Urban Cervical Cancer Disparities N/A
Recruiting NCT05916911 - Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR) Phase 4
Completed NCT01030562 - Immunogenicity of Off-Schedule Dosing of HPV Vaccine